A few epidemiologic studies have suggested that blood transfusion may be a risk factor for non-Hodgkin's lymphoma. The authors tested this hypothesis in a population-based, case-control study, using pathologically verified non-Hodgkin's lymphoma cases and transfusion documented via medical records. In 221 age-and sexmatched case-control pairs from Olmsted County, Minnesota, in 1975Minnesota, in -1993, the authors observed an odds ratio of 0.84 (95% confidence interval 0.50-1.41) for history of transfusion and non-Hodgkin's lymphoma. There also was no apparent association between transfusion and non-Hodgkin's lymphoma in any subgroup analysis. Results do not support the hypothesis that blood transfusion contributes to the occurrence of non-Hodgkin's lymphoma. Am J Epidemiol 1999; 149:1113-18. 
Incidence rates of non-Hodgkin's lymphoma have been increasing 3-$ percent per year in the United States since the early 1970s (1), reaching an estimated 52,700 cases in 1996. Certain pesticides (2), kidney transplantation, Sjogren's syndrome (3) , and human immunodeficiency syndrome (1) are risk factors for non-Hodgkin's lymphoma. The increased risk of nonHodgkin's lymphoma in patients with primary immunodeficiency, in solid transplant recipients, and in patients treated with immunosuppressive drugs suggests immunosuppression as a possible etiologic mechanism (3) (4) (5) .
In addition to these risk factors, blood transfusion has recently been suggested as a risk factor for nonHodgkin's lymphoma. A prospective, populationbased study by Cerhan et al. (6) found that women aged 55-69 years who self-reported that they had received a blood transfusion during their lives were at twice the risk for non-Hodgkin's lymphoma as women not reporting transfusion history. Similarly, Blomberg et al. (7) found a threefold elevated incidence of non-Hodgkin's lymphoma among 3,177 Swedish blood recipients compared with expected non-Hodgkin's lymphoma rates. In a second cohort of 29,910 hospitalized patients followed for 3-9 years, the same authors found a similar result: history of blood transfusion carried a relative risk of 3.45 for non-Hodgkin's lymphoma (7) . The mechanism underlying this association has not been determined. It is clear that viruses can be transmitted through blood transfusion (8) , and a viral etiology has been shown for Burkitt's lymphoma, T-cell leukemia, hepatocellular carcinoma, and certain papillomas (8) . The immunosuppressive effects of allogenic blood (9) have also been hypothesized as a potential mechanism (6, 7) , consistent with the increased risk of non-Hodgkin's lymphoma in immunosuppressed patients.
The goal of this population-based, case-control study was twofold. The first aim was to corroborate the previous findings that risk of non-Hodgkin's lymphoma is associated positively with a documented history of blood transfusion. The second was to determine if there were specific indications for transfusion or particular grades of non-Hodgkin's lymphoma that were associated with an increased risk of this disease.
MATERIALS AND METHODS
The community of Olmsted County was well suited for a population-based study (10, 11) , because it is relatively isolated from other urban areas and the community residents obtain medical care from a handful of providers (Mayo Clinic and Olmsted Medical Center). Further, these providers use a unit medical record that contains all records related to the medical care of that patient, whether in the inpatient, outpatient, emergency room, or nursing home setting. All diagnoses (clinical and pathologic) and procedures performed at the Mayo Clinic have been indexed; a separate index for other providers of care to Olmsted County residents has been maintained under the auspices of the Rochester Epidemiology Project. Patients who were initially diagnosed at Olmsted Medical Center were referred to the Mayo Clinic, where either the initial biopsy or a second biopsy was interpreted by a Mayo Clinic pathologist. Both the diagnostic indexing system and the pathology registry were used to identify all Olmsted County residents aged 18 years and older with a confirmed pathologic diagnosis of non-Hodgkin's lymphoma from 1975 to 1993. This was cross-referenced with an independent lymphoma database maintained by the Hematology Division at the Mayo Clinic. Once identified, the medical records of potential cases were reviewed to exclude patients who did not reside in Olmsted County, Minnesota, for at least 1 year prior to the nonHodgkin's lymphoma diagnosis (to remove patients who may have moved near the Mayo Clinic to obtain care for a medical condition). The case's first date of a pathology report that was diagnostic of non-Hodgkin's lymphoma was designated as the "index date."
An enumeration of Olmsted County residents was available that captured nearly 96 percent of the census population (11) . A previous random digit dialing survey indicated that all residents who were telephoned had a Mayo system clinic number (12) . Thus, the enumeration provided an appropriate source of controls. One potential control for each non-Hodgkin's lymphoma case was selected from residents who had lived in the county at least 1 year prior to the case's index date and who had no history of non-Hodgkin's lymphoma. The control was matched to each case on the basis of age (±3 years of the case's index date), sex, and closest clinic number. As clinic numbers are assigned sequentially, the closest clinic number ensured that cases and controls have similar enrollment dates within the Mayo system, thus matching for exposure opportunity.
The medical records of cases and controls were reviewed, and information was abstracted onto a standardized form, beginning with the most recent time period (1993) and proceeding backward to achieve sample size (n = 221). The anticipated sample size of 221 (90 discordant pairs) yielded a 90 percent chance of detecting at least a twofold increased risk with a = 0.05 at the anticipated lifetime prevalence of transfusion of 20 percent in the controls (6) . The abstraction of cases and controls was alternated by the abstractor every 20 medical records to reduce potential bias related to abstractor drift. Abstracted information included age, sex, status at last follow-up, prior history of cancer, radiation exposure, chemotherapy, occupation, tobacco use, alcohol use, family history of lymphoma or other cancer, anemia, steroid exposure, connective tissue disorders, and autoimmune diseases, such as rheumatoid arthritis. Information abstracted to describe non-Hodgkin's lymphoma cases included the source of tissue, site of primary involvement, and cell type, all of which were identified on the initial pathology report. Documented transfusion history, the primary exposure of interest, included date, number of units transfused, type of blood product (red blood cells, whole blood, and so on), and reason for transfusion (surgery, bleeding disorder, and so on). Because recent transfusions could have been for subclinical non-Hodgkin's lymphoma, cases and controls whose only transfusions were less than 6 months prior to the index date were coded as not exposed. For secondary analyses, the patient's own report of transfusion history was abstracted from a self-administered health history form routinely found in Mayo charts.
Statistical analyses were performed with a method that accounted for the matched design. Conditional logistic regression was used to estimate odds ratios and their respective confidence intervals. The primary analysis estimated the association between blood transfusion history (yes/no) and outcome (nonHodgkin's lymphoma). Secondary analyses were performed to estimate the risk in strata determined by age, sex, and the number of units of blood transfused.
RESULTS
Of the 221 matched pairs, 132 were women, and 89 were men. The median age of the cases was 71.3 (range, 19.7-95.0) years. The median time in the Mayo system prior to the index date was 37 years for both the cases and the controls; 95 percent of the cases and 94 percent of the controls were in the system at least 5 years. The cases and controls were similar relative to history of diabetes, anemia, family history of lymphoma or other cancer, occupational exposure to pesticides, tobacco and alcohol use, therapeutic and nontherapeutic radiation exposure, history of chemotherapy, and exposure to steroids, phenytoin, digoxin, and/or methotrexate (table  1) . Prior history of cancer was less common in nonHodgkin's lymphoma cases than controls (odds ratio = 0.54, 95 percent confidence interval 0.32-0.89).
Several conditions were too rare to be analyzed. They included Sjogren's syndrome, human immunodeficiency virus, human T-lymphotrophic virus, sprue, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, other connective tissue diseases, secondary cryoglobulinemia, Hashimoto's disease/thyroiditis, autoimmune hemolytic anemia, idiopathic thrombocy- 
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topenic purpura, cold agglutinin, epilepsy, and chronic lymphocytic leukemia. Overall, the prevalence of transfusion was 18 percent in cases and 20 percent in controls. There was no evidence of a significant association between nonHodgkin's lymphoma and history of blood transfusions (odds ratio = 0.84, 95 percent confidence interval 0.50-1.41; table 2). Transfusion history was not found to be associated with any particular grade of nonHodgkin's lymphoma (table 2) . There also was no evidence of a significant association between transfusion and non-Hodgkin's lymphoma when stratified by age or sex (table 3) . In comparison with no transfusions, the odds ratio for 1-3 transfusions was 0.58 (95 percent confidence interval 0.30-1.12) and, for >3 transfusions, it was 1.56 (95 percent confidence interval 0.68-3.59). Finally, the odds ratio was 0.88 (95 percent confidence interval 0.44-1.77) based on the selfreported history of transfusion routinely recorded in the chart (147 pairs had data). 1 .00(0.14-7.10) * Case yes, control yes = case and control both positive for history of transfusion; case yes, control no = case positive, control negative; case no, control yes = case negative, control positive; case no, control no = case and control both negative.
t Numbers in parentheses, 95% confidence interval. i Low grade NHL includes the following: diffuse, small lymphocytic; follicular, small cleaved; follicular, mixed; nodular lymphocytic, poorly differentiated; nodular mixed, histiocytic and lymphocytic; and diffuse lymphocytic, well differentiated.
§ Intermediate grade NHL includes the following: follicular, large cell; diffuse, poorly differentiated/small cleaved; diffuse, mixed; diffuse, large cell; nodular histiocytic; diffuse lymphocytic, poorly differentiated; and diffuse mixed, histiocytic and lymphocytic.
H High grade NHL includes the following: immunoblastic; small noncleaved/Burkitt's lymphoblastic; diffuse histiocytic; and diffuse undifferentiated.
# Other types include the following: Mantle cell lymphoma; cutaneous T-cell; composite lymphoma; T-cell lymphoma; lymphoma unclassified; large cell sarcoma; reticular cell sarcoma; nodular lymphocytic, well differentiated; and immunoblastic lymphadenopathy, NHL, unclassified. * Case yes, control yes = case and control both positive for history of transfusion; case yes, control no = case positive, control negative; case no, control yes = case negative, control positive; case no, control no = case and control both negative.
t Numbers in parentheses, 95% confidence interval.
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DISCUSSION
In contrast with the Iowa Women's Health Study (relative risk = 2.2, 95 percent confidence interval 1.35-3.58) (6) and the Swedish study (standardized mortality ratio = 2.70, 95 percent confidence interval 1.44-4.62) (7), we found no evidence to suggest that a significant association between non-Hodgkin's lymphoma and blood transfusion exists. The controls in this study were, in fact, slightly more likely to have received a blood transfusion 6 months prior to the index date than were the cases. There also was no evidence to suggest an association between exposure to blood transfusion and non-Hodgkin's lymphoma when stratified by the patient's age, sex, or grade of nonHodgkin's lymphoma. Finally, there was no trend between the number of units of blood transfused and the risk of non-Hodgkin's lymphoma.
With negative results, power is always a concern. An inadequate number of discordant pairs, however, is an unlikely explanation for failing to find an association. Our sample size estimates assumed that we would obtain 90 discordant pairs. With 57 discordant pairs achieved, we had 72 percent (83 percent) power to detect a twofold (2.2-fold) increase in the risk of nonHodgkin's lymphoma among those with a prior history of transfusion. However, the power in subgroup analyses was markedly less. Random misclassification of exposure (transfusion history) could have masked a real association, but this seems unlikely since transfusions were well documented by medical records. Furthermore, all cases were pathologically confirmed.
A history of other cancer prior to the index date was statistically significantly and inversely associated with non-Hodgkin's lymphoma. This was surprising as previous studies suggest that prior cancer is a risk factor for non-Hodgkin's lymphoma (13) (14) (15) . No other abstracted variable was found to be a risk factor for non-Hodgkin's lymphoma, including diabetes, which has been associated inconsistently with non-Hodgkin's lymphoma (13, 16, 17) .
A potential limitation of this study was that the abstractor could not be blinded to case status. The use of standardized forms with a defined protocol should have helped to avoid bias. A second potential limitation is the unavailability of transfusion history prior to receiving medical care within Olmsted County. While cases were matched to controls on the index date, cases may have had more transfusions prior to enrollment than did controls, biasing our results toward no association. However, the median time in the Mayo system was rather long-36 years. A third potential limitation is that by design the controls had to have a system registration within the same year as the index date of the cases, which may have yielded a disproportionate number of controls with chronic conditions than would be found in the total Olmsted County population. However, approximately two thirds of the 65-to 74-year-old Olmsted County residents are registered each year (11) . A sensitivity analysis suggests that, even if the one third of unsampled potential controls happened to have never been transfused, their inclusion likely would have yielded an odds ratio of only 1.43 (95 percent confidence interval 0.82-2.50). Furthermore, when those case-control pairs in which the control had cancer were eliminated (n = 53), the association with transfusion still was not found to be significant (odds ratio = 0.87, 95 percent confidence interval 0.48-1.58).
At this time, it is difficult to understand whether there is an association between blood transfusion and non-Hodgkin's lymphoma. Two (18, 19) of three (18) (19) (20) additional studies published since the onset of this study have suggested some increase in nonHodgkin's lymphoma risk with transfusion. A casecontrol study by Memon and Doll (18) identified over 12,000 individuals in 41 major hospitals in England, Wales, and Scotland who had received a blood transfusion as infants. The incidence of non-Hodgkin's lymphoma in individuals aged 15-49 years was twice that expected; however, because of small numbers, these results were not statistically significant (observed = 4, expected = 1.85, relative risk estimate = 2.16, 95 percent confidence interval 0.59-5.54). In individuals aged 1-14 years, no association was found between blood transfusion and non-Hodgkin's lymphoma.
In a second case-control study, 280 of 426 cases of non-Hodgkin's lymphoma and 1,827 controls returned a questionnaire that assessed, among many items, transfusion history (19) . There was an increased risk of non-Hodgkin's lymphoma in patients who had been transfused 1 year or more prior to filling out the questionnaire adjusted for age and sex (odds ratio = 1.74, 95 percent confidence interval 1.24-2.44). For 185 patients, histologic diagnoses and staging results were known. Significant associations were found for those diagnosed with low-grade non-Hodgkin's lymphoma of the nodal B-cell chronic lymphocytic leukemia or immunocytoma type and for high-grade extranodal lymphoma according to the Kiel classification of lymphoma. For all other types of non-Hodgkin's lymphoma, no significant associations were found.
In contrast with these two studies (18, 19) , Adami et al. (20) recently reported no association between transfusion (as determined from a population-based transfusion registry) and non-Hodgkin's lymphoma in a population-based, nested case-control study in Sweden (odds ratio = 0.93, 95 percent confidence interval 0.72-1.23).
The four positive studies (6, 7, 18, 19) used cohort (6, 7, 18) and case-control (19) study designs and used either self-report (6, 19) or medical records (7, 18) to ascertain transfusion exposure. With a single exception (19) , these studies were based on small numbers of non-Hodgkin's lymphoma cases; however, the total number of cases combined was over 400, and the relative risk estimates of about 2.0 across all studies were strikingly similar. The null studies (20, this one) were population-based, case-control studies, one nested in a cohort (20) , and both used medical records to ascertain transfusion exposure. Together, these two studies had nearly 600 cases of non-Hodgkin's lymphoma. Only one study has evaluated confounding beyond age and sex (6, 13) , but it found little evidence for confounding by diabetes, prior cancer, diet, or other potential nonHodgkin's lymphoma risk factors. Finally, transfusion history may be a risk factor only for particular subtypes of non-Hodgkin's lymphoma (21) , and limited data suggest that the association may be strongest with low-grade non-Hodgkin's lymphoma (19) . In summary, these fragmentary and conflicting results are not easily reconciled. Given the high number of transfusions each year, further data are required to help address this hypothesis.
